Generic drug: enasidenib
Brand name: Idhifa
What is Idhifa (enasidenib), and how does it work?
Idhifa (enasidenib) is a prescription medicine used to treat people with acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation whose disease has come back or has not improved after previous treatment(s). It is not known if Idhifa is safe and effective in children.
What are the side effects of Idhifa?
Patients treated with Idhifa have experienced symptoms of differentiation syndrome, which can be fatal if not treated. Symptoms may include fever, dyspnea, acute respiratory distress, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, lymphadenopathy, bone pain, and hepatic, renal, or multi-organ dysfunction. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution.
Idhifa may cause serious side effects, including:
The most common side effects of Idhifa include:
Tell your healthcare provider if you have any changes to the color of your skin or the whites of your eyes.
Your healthcare provider will monitor you for side effects during treatment and may tell you to stop taking Idhifa if you develop certain side effects.
These are not all the possible side effects of Idhifa.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is the dosage for Idhifa?
- Select patients for the treatment of AML with Idhifa based on the presence of IDH2 mutations in the blood or bone marrow. Information on FDA-approved tests for the detection of IDH2 mutations in AML is available at http://www.fda.gov/CompanionDiagnostics.
- The recommended dosage of Idhifa is 100 mg taken orally once daily with or without food until disease progression or unacceptable toxicity. For patients without disease progression or unacceptable toxicity, treat for a minimum of 6 months to allow time for clinical response.
- Do not split or crush Idhifa tablets. Administer Idhifa tablets orally about the same time each day. If a dose of Idhifa is vomited, missed, or not taken at the usual time, administer the dose as soon as possible on the same day, and return to the normal schedule the following day.
Monitoring And Dosage Modifications For Toxicities
Assess blood counts and blood chemistries for leukocytosis and tumor lysis syndrome prior to the initiation of Idhifa and monitor at a minimum of every 2 weeks for at least the first 3 months during treatment. Manage any abnormalities promptly.
Interrupt dosing or reduce dose for toxicities. See Table 1 for dosage modification guidelines.
Table 1: Dosage Modifications for Idhifa-Related Toxicities
|Adverse Reaction||Recommended Action|
|*Grade 1 is mild, Grade 2 is moderate, Grade 3 is serious, Grade 4 is life-threatening.|
What drugs interact with Idhifa?
Effect Of Idhifa On Other Drugs
OATP1B1, OATP1B3, And BCRP Substrates
- Idhifa is an OATP1B1, OATP1B3, and BCRP inhibitor. Coadministration of Idhifa increases the exposure of OATP1B1, OATP1B3, and BCRP substrates, which may increase the incidence and severity of adverse reactions of these substrates.
- Decrease the dosage of OATP1B1, OATP1B3, and BCRP substrate(s) as recommended in the respective prescribing information, and as clinically indicated.
Certain P-glycoprotein (P-gp) Substrates
- Idhifa is a P-gp inhibitor. Coadministration of Idhifa increases the exposure of P-gp substrates, which may increase the incidence and severity of adverse reactions of these substrates.
- For a P-gp substrate where small concentration changes may lead to serious adverse reactions, decrease the dose or modify the dosing frequency of such a P-gp substrate and monitor for adverse reactions as recommended in the respective prescribing information.
Is Idhifa safe to use while pregnant or breastfeeding?
- Based on animal embryo-fetal toxicity studies, Idhifa can cause fetal harm when administered to a pregnant woman.
- There are no available data on Idhifa use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage.
- There are no data on the presence of enasidenib or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production.
- Because of the potential for adverse reactions in the breastfed child, advise women not to breastfeed during treatment with Idhifa and for at least 2 months after the last dose.
Latest Cancer News
Daily Health News
Multimedia: Slideshows, Images & Quizzes
Blood Cancer Types: Leukemia, Lymphomas, Myelomas, and More
Types of blood cancers include leukemia, lymphomas, multiple myelomas, and others discussed in this slideshow. Symptoms may...
Cancer: Guide to Leukemia
Learn about the common types and stages of leukemia, who gets it, symptoms, tests, treatments, and more. People with blood cancer...
What do you know about leukemia? Did you know there are different types? What are the symptoms? Take the Leukemia Quiz and test...
Related Disease Conditions
What Is the Life Expectancy of a Person With Leukemia?
Leukemia is a group of cancers of the blood affecting the white blood cells. White blood cells are the infection-fighting cells of the body. In adults, leukemia is most common in people older than 55 years, with the average age of diagnosis being 66 years. It is also one of the most common cancers in children and adults younger than 20 years. The survival rate is higher for younger people.
Leukemia is a type of cancer of the blood cells in which the growth and development of the blood cells are abnormal. Strictly speaking, leukemia should refer only to cancer of the white blood cells (the leukocytes) but in practice it can apply to malignancy of any cellular element in the blood or bone marrow, as in red cell leukemia (erythroleukemia).
How Does Leukemia Kill?
Leukemia is a cancer of the white blood cells of the bone marrow. Patients with leukemia have an over-production of a particular blood cell type in the body, the white blood cells (cells that fight infection, and provide immunity).
Survival Rate for Acute Lymphoblastic Leukemia
The prognosis depends on the type of leukemia, the extent of the disease, age of the patient, and the general condition of the patient. Some patients can go into complete remission. The average five-year survival rate of leukemia is 60-65%.
Leukemia: Signs, Symptoms, And Complications
Leukemia results when the genetic material (DNA) of a single cell in the bone marrow transforms, this is called a mutation. A mutated cell does not perform body function, but it eats away the nutrition meant for the normal cells.
Childhood Acute Lymphoblastic Leukemia (ALL)
Childhood acute lymphoblastic leukemia is the most common type of cancer in children. Symptoms and signs include fever, easy bruising, bone or joint pain, weakness, loss of appetite, and painless lumps in the neck, underarm, stomach, or groin. Treatment depends upon staging and may include chemotherapy, radiation, or stem cell transplant.
What Are the Stages of Chronic Lymphocytic Leukemia?
Chronic lymphocytic leukemia is a cancer of the blood and bone marrow. With this type of cancer, the marrow creates too many abnormal lymphocytes. There are five stages of chronic lymphocytic leukemia.
Treatment & Diagnosis
- Leukemia FAQs
- Evolution of Treatment for a Rare Type of Leukemia
- Gleevec and Chronic Myeloid Leukemia
- How Familes Cope with a Leukemia Diagnosis
- Coping with a Bad Disease - Community Counts
- A Family's Leukemia Diary - Coping
- Is Multiple Myeloma the Same as Leukemia?
- Does Folic Acid Prevent Leukemia?
- Can Folic Acid Prevent Leukemia?
- Chronic Myelogenous Leukemia (CML)
Medications & Supplements
Health Solutions From Our Sponsors
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.